X

Trial Profile

Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Jun 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azeliragon (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Registrational
Acronyms STEADFAST-Extension
Sponsors vTv Therapeutics LLC

Most Recent Events

30 Apr 2018 Planned End Date changed from 1 Nov 2020 to 1 Jun 2018.
30 Apr 2018 Planned primary completion date changed from 1 Nov 2020 to 9 May 2018.
09 Apr 2018 Status changed from recruiting to discontinued, according to vTv Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com